Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 11/20 | 0.49 |
| ▸ | UBA3 | Q8TBC4 | 11/20 | 0.49 |
| ▸ | UBA1 | P22314 | 1/20 | 0.40 |
| ▸ | UBE2E1 | P51965 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 7/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 5/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 5/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283339 | 0.88 | NAE1 (0.62) | NAE1UBA3BTKSAE1UBA2 | |
| SCHEMBL782583 | 0.86 | NAE1 (0.66) | NAE1UBA3UBA1UBE2E1SAE1 | |
| SCHEMBL10283691 | 0.86 | NAE1 (0.52) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL805407 | 0.86 | NAE1 (0.61) | NAE1UBA3UBA1UBE2E1SAE1 | |
| SCHEMBL805369 | 0.83 | NAE1 (0.46) | NAE1UBA3BTKSAE1UBA2 | |
| SCHEMBL805417 | 0.82 | NAE1 (0.49) | NAE1UBA3UBA1UBE2E1SAE1 | |
| SCHEMBL805377 | 0.81 | NAE1 (0.49) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL805382 | 0.79 | NAE1 (0.43) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL805371 | 0.78 | NAE1 (0.45) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL783173 | 0.76 | NAE1 (0.66) | NAE1UBA3SAE1UBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885UBA1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.